METHOD OF ESTIMATING THE EFFICACY OF FLUVOXAMINE THERAPY FOR TREATING DISORDERS ACCOMPANIED BY DEVELOPMENT OF DEPRESSIVE SYMPTOMS Russian patent published in 2020 - IPC A61K31/15 G01N33/50 C12Q1/6827 A61P25/18 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to pharmacogenetics, clinical pharmacology, psychiatry, addictology, and can be used for selecting the fluvoxamine antidepressant dose. What is described is a method for predicting the clinical effectiveness of fluvoxamine therapy for treating disorders accompanied by development of depressive symptoms by genotyping using polymorphic markers of CYP2D6 genes. Value of the parameter P is calculated, which is the estimated value of change in the rate of biotransformation of fluvoxamine, depending on the state of genetic polymorphism in each specific patient. If the fluvoxamine biotransformation rate is deviated by 50 % and more, a drug substitution recommendation is given. If slowing down the biotransformation of fluvoxamine by less than 50 %, a dose reduction recommendation is given. When accelerating the biotransformation of fluvoxamine by less than 50 %, a higher dose recommendation is given.

EFFECT: disclosed method has high accuracy, information value and objectivity, since based on a method for reliable assessment of genetic apparatus and algorithms included in meta-analyzes of authoritative consortia when calculating similar values for other drugs.

1 cl, 1 tbl